FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction (FLOWER-MI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02943954|
Recruitment Status : Active, not recruiting
First Posted : October 25, 2016
Last Update Posted : November 19, 2021
Although current guidelines recommend fractional flow reserve (FFR) to identify haemodynamically relevant coronary lesion(s) in stable patients when evidence of ischaemia is not available (Class I, Level of Evidence: A), no published study has assessed the usefulness of FFR to guide percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI) patients with multi-vessel disease (MVD).
The main objective of this study is to determine whether, in STEMI patients with MVD amenable to PCI, the use of FFR in addition to angiography will improve cardiovascular outcomes, compared with the current practice of angiography- guided PCI, by improving the appropriateness of revascularisations by assessing the relevance of non-culprit lesions in the context of STEMI with multivessel coronary artery disease.
The secondary objective is to assess the safety and the cost-effectiveness of the FFR-guided strategy compared to the angiography-guided strategy.
|Condition or disease||Intervention/treatment||Phase|
|Acute ST Segment Elevation Myocardial Infarction Acute Myocardial Infarction Multi Vessel Coronary Artery Disease||Procedure: Angiography guided PCI Device: Fractional Flow Reserve (FFR)||Not Applicable|
The optimal revascularisation strategy in STEMI patients with MVD is currently debated. Recent data suggest that MV-PCI may be the most appropriate option for treating such patients. Consequently, the real challenge becomes to define what MVD is, in the context of acute MI, in order to limit revascularisation by PCI to vessels that truly need it. Visual estimation of the degree of coronary stenoses is a poor indicator of their haemodynamic severity. FFR is precisely designed and recommended in current guidelines to provide objective guidance for the functional assessment of lesion severity during coronary angiography in stable patients, but it has not been validated in STEMI patients with MVD. The purpose of the present trial will therefore be to investigate the relevance of FFR to guide the revascularisation management of patients at the acute stage of STEMI.
STEMI patients with successful culprit lesion PCI (primary, rescue or pharmaco-invasive) and ≥ 50% diameter stenosis by visual estimate, in which revascularization is contemplated and judged amenable to PCI in at least one additional non-culprit lesion will be randomized into two groups: angiography-guided PCI or FFR-guided PCI.
If the patient is randomized to the angiography-guided PCI, all the lesions indicated beforehand will be treated. If the patient is randomized to the FFR-guided PCI, measurements of FFR of non-infarct related lesion(s) will be performed and only those lesions with a FFR ≤ 0.80 will be treated.
The use of drug-eluting stents is encouraged in both strategies. All patients will receive optimal medical therapy (including dual antiplatelet therapy, beta-blockers, statins, ACE-I or ARB) as recommended in international guidelines in both strategies.
Clinical follow-up will be performed at discharge, 30-day, 6 month and one-year. Rates of major adverse cardiac events, functional class and number of anti-anginal medications used will be collected. If the patient has been rehospitalized since index hospital discharge, the discharge summary and all relevant information will be collected.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1170 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction|
|Actual Study Start Date :||December 2016|
|Actual Primary Completion Date :||October 24, 2020|
|Estimated Study Completion Date :||January 2022|
Angiography guided PCI
Revascularisation of non-culprit lesions guided by PCI
Procedure: Angiography guided PCI
FFR guided PCI
Revascularisation of non-culprit lesions guided by FFR measurement
Device: Fractional Flow Reserve (FFR)
- Rate of major adverse cardiac events [ Time Frame: 1 year ]Number of deaths, myocardial infarctions and unplanned hospitalization leading to urgent revascularizations at one year.
- Deaths [ Time Frame: 1 year ]
- Myocardial infarctions [ Time Frame: 1 year ]
- Repeat revascularizations [ Time Frame: 1 year ]
- Rate of nonculprit artery target lesion treated by urgent revascularization [ Time Frame: 1 year ]
- Rates of major adverse cardiac events at 30 days and 6 months [ Time Frame: 30 days and 6 months ]
- Rehospitalization for angina during the follow up period [ Time Frame: 1 year ]
- Procedure time [ Time Frame: 5 days ]
- Functional class at 1 year [ Time Frame: 1 year ]The functional class is assessed with the use of the Canadian Cardiovascular Society classification of angina.
- Health-related quality of life [ Time Frame: 1 year ]Health-related quality of life is assessed by the European Quality of Life-5 Dimensions [EQ-5D] questionnaires
- Anti-anginal medications used [ Time Frame: 1 month, 6 months and 1 year ]Number of anti-anginal medications used
- Cost effectiveness [ Time Frame: 1 year ]Incremental cost effectiveness ratio (ICER) using the composite endpoint (all-cause death, myocardial infarctions and repeat revascularizations).
- Cost utility [ Time Frame: 1 year ]Incremental cost-utility ration (ICUR) using quality-adjusted life years (QALYs)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02943954
|Paris, France, 75015|
|Principal Investigator:||Etienne PUYMIRAT, MD||AP - HP, Hôpital Europeen Georges-Pompidou, Paris, France|